≪p>differential Metabolic Alterations and Biomarkers Between Gastric Cancer and Colorectal Cancer: A Systematic Review and Meta-Analysis</p>

Jingshen Tian,Handong Wang,Huihui Yin,Nannan Zhang,Jianqiu Zhou,Zhiping Long,Chengwei Wu,Zhengzi Liang,Kun Xie,Shuo Li,Liangliang Li,Zhiyong Wu,Volontovich Daria,Yashuang Zhao,Fan Wang,Maoqing Wang
DOI: https://doi.org/10.2147/ott.s247393
IF: 4
2020-01-01
OncoTargets and Therapy
Abstract:Purpose: Numerous metabolomics studies have been conducted to detect the metabolic mechanisms and biomarkers related to gastric cancer and colorectal cancer.Because of the common metabolic features between gastric cancer and colorectal cancer, a differential diagnosis is difficult.Here, we performed a systematic review and meta-analysis to identify differential metabolic biomarkers between these two types of cancers.Materials and Methods: PubMed, Embase, and ScienceDirect were searched to identify all metabolomics studies of gastric cancer and colorectal cancer published up to September 2018.Differential metabolites or altered pathways were extracted.The intersections and differences for these metabolites and pathways between gastric cancer and colorectal cancer were compared.Candidate biomarker sets for diagnosis were proposed from biofluid or feces by comparing them with tumor tissues.Results: Totally, 24 and 65 studies were included in gastric cancer and colorectal cancer, and 223 and 472 differential metabolites were extracted, respectively.Eight pathways were reproducibly enriched in blood, tissue and urine in gastric cancer, while, 11 pathways were reproducibly enriched in blood, urine, feces and tissue in colorectal cancer.Candidate metabolic biomarker sets in blood, urine, or feces for these two cancers were proposed.We found 27 pathways (categorized into eight classifications) common to both cancers, five pathways involving 35 metabolites enriched only in gastric cancer, and eight pathways involving 54 metabolites enriched only in colorectal cancer. Conclusion:The altered metabolic pathways showed signatures of abnormal metabolism in gastric cancer and colorectal cancer; the potential metabolic biomarkers proposed in this study have important implications for the prospective validation of gastric cancer and colorectal cancer.
What problem does this paper attempt to address?